Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients

Inclusion Criteria: 1. Patient with a previous diagnosis of aplastic anemia and had no response or relapsed following at least one treatment course in a period time of ≥ 6 months of immunosuppression containing CsA or CsA+anti-thymocyte globulin (ATG); 2. Current diagnosis of aplastic anemia by bone marrow biopsy; 3. did not receive HSCT nor were HSCT candidates; 4. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0-2; 5. Patient with QTcF (Fridericia's QT correction formula) at screening \<450 msec, or \<480 msec with bundle branch block, as determined via the mean of a triplicate ECG and assessed at site. 6. Subjects are able to understand and comply with protocol requirements and instructions and have signed and dated informed consent. Exclusion Criteria: 1. Congenital aplastic anemia; 2. Presence of chromosomal aberration; 3. Evidence of a clonal hematologic bone marrow disorder on cytogenetics; 4. Have any concomitant malignancies and must be fully recovered from treatment for any other malignancy and have been disease-free for 5 years; 5. AST or ALT ≥3 times the upper limit of normal; 6. Serum creatinine, total bilirubin, or alkaline phosphatase \>1.5 x ULN; 7. Cardiac disorder (NYHA) functional classification Grade II/III/IV; 8. Past history of thromboembolic event (including anti-phospholipid antibody syndrome) and current use of anticoagulants; 9. Infection not adequately responding to appropriate therapy; 10. Other known or suspected underlying primary immunodeficiency; 11. Prior treatment with eltrombopag, romiplostim, or any other TPO (thrombopoietin) receptor agonist; 12. Pregnant or nursing (lactating) woman;